<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560218</url>
  </required_header>
  <id_info>
    <org_study_id>122/2563</org_study_id>
    <nct_id>NCT04560218</nct_id>
  </id_info>
  <brief_title>Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT</brief_title>
  <official_title>Sublingual Versus Intrauterine MISOPROSTOL in Addition to Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Objective:&#xD;
&#xD;
      Primary outcome&#xD;
&#xD;
      -To compare efficacy Intrauterine vs Sublingual MISOPROSTOL in addition to Oxytocin in&#xD;
      reducing blood loss of post-cesarean section in high risk women&#xD;
&#xD;
      Secondary outcome&#xD;
&#xD;
      -To study Hemoglobin/Hematocrit change, need of uterotonic agents, need of blood transfusion,&#xD;
      adverse drug event of Intrauterine vs Sublingual Misoprostol plus Oxytocin compare to&#xD;
      Oxytocin alone&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      -Intrauterine MISOPROSTOL plus Oxytocin is not inferior to Sublingual MISOPROSTOL plus&#xD;
      Oxytocin in reducing blood loss of post-cesarean section in high risk women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Design: Double-blind Randomized Placebo Controlled Trial&#xD;
&#xD;
      Subject: Singleton pregnancy GA 34 wk or more with high risk for postpartum hemorrhage&#xD;
      undergo cesarean section with spinal anesthesia in Rajavithi Hospital&#xD;
&#xD;
      Allocated to 3 groups&#xD;
&#xD;
        -  group1: Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo&#xD;
           Intrauterine 2 tab&#xD;
&#xD;
        -  group2: Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo&#xD;
           sublingually 2 tab&#xD;
&#xD;
        -  group3: Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2&#xD;
           tab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>operation time</time_frame>
    <description>total blood loss estimated by Anesthesiologist team</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin/Hematocrit change</measure>
    <time_frame>until 24 hours post-operation</time_frame>
    <description>compare before/after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of uterotonic agents</measure>
    <time_frame>until 24 hours post-operation</time_frame>
    <description>number of uterotonic agents need and type of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of blood transfusion</measure>
    <time_frame>until 24 hours post-operation</time_frame>
    <description>number of blood transfusion need</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse drug event</measure>
    <time_frame>until 24 hours post-operation</time_frame>
    <description>adverse drug event of Misoprostol and Oxytocin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women</condition>
  <arm_group>
    <arm_group_label>Uterotonic agents group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uterotonic agents group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uterotonic agents group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual Misoprostol</intervention_name>
    <description>apply drug by Anesthesiologist</description>
    <arm_group_label>Uterotonic agents group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrauterine Misoprostol</intervention_name>
    <description>apply drug by surgeon at uterine cornu</description>
    <arm_group_label>Uterotonic agents group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥35 ปี&#xD;
&#xD;
          -  Previous PPH&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Fetal macrosomia&#xD;
&#xD;
          -  Polyhydramnios&#xD;
&#xD;
          -  Induction/Augmentation of Labour&#xD;
&#xD;
          -  Prolonged Labour&#xD;
&#xD;
          -  Grand multiparity&#xD;
&#xD;
          -  Preeclampsia&#xD;
&#xD;
          -  Myoma Uteri&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Maternal fever/ Tripple I can't excluded&#xD;
&#xD;
          -  coagulopathy&#xD;
&#xD;
          -  Placenta previa/ adherens/ abruptio placenta&#xD;
&#xD;
          -  Allergy to Prostaglandins/Oxytocin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum hemorrhage, Cesarean section, Sublingual Misoprostol, Intrauterine Misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

